AU Patent

AU2011206979B2 — Treatment of cardiac conditions

Assigned to Zealand Pharma AS · Expires 2015-09-10 · 11y expired

What this patent protects

The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic age…

USPTO Abstract

The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon.

Drugs covered by this patent

Patent Metadata

Patent number
AU2011206979B2
Jurisdiction
AU
Classification
—
Expires
2015-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Zealand Pharma AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.